Loading
A phase 2 trial of HLX43 DOSE 1 in nasopharyngeal carcinoma, run by Shanghai Henlius Biotech, now recruiting.
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy is a phase 2 interventional study registered as NCT06839066 by Shanghai Henlius Biotech, with 70 participants planned, started 2025-04-02 and due to reach its primary completion in 2026-11-22. Interventions recorded: HLX43 DOSE 1, HLX43 DOSE 2 and HLX43 DOSE 3.
Shares Recurrent and metastatic nasopharyngeal carcinoma, Nasopharyngeal carcinoma and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Nasopharyngeal carcinoma and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.